Tag: Indole alkaloid / mu-opioid agonist

7-Hydroxymitragynine (7-OH) is a terpenoid indole alkaloid isolated from the leaves of Mitragyna speciosa Korth. (kratom), first characterized by Ponglux, Takayama, and colleagues in 1994 as a minor constituent comprising less than 2 percent of the total alkaloid content of Thai kratom leaf material [1]. The compound is the C7-hydroxylated derivative of mitragynine, the principal alkaloid of kratom, and is generated both as a natural biosynthetic product in the plant and as a hepatic metabolite of mitragynine through cytochrome P450 3A (CYP3A) isoform-mediated oxidation in mammalian systems [2, 3]. 7-Hydroxymitragynine binds the mu-opioid receptor (MOR) with high affinity (Ki approximately 7 to 70 nM depending on the assay system and radioligand employed), approximately 5- to 46-fold greater than mitragynine, and produces antinociception in rodent hot-plate and tail-flick models at potencies approximately 13-fold greater than morphine on a weight basis after subcutaneous administration and with superior oral bioactivity [4, 5]. The compound functions as a partial agonist at the mu-opioid receptor, with G-protein biased signaling that results in minimal recruitment of beta-arrestin-2, a downstream effector linked to opioid-induced respiratory depression, constipation, and tolerance in the beta-arrestin hypothesis of opioid pharmacology [6, 7]. At delta-opioid (DOR) and kappa-opioid (KOR) receptors, 7-hydroxymitragynine acts as a competitive antagonist, a selectivity profile that distinguishes it from classical full opioid agonists such as morphine and fentanyl [8].

The pharmacokinetic profile of 7-hydroxymitragynine in humans has been characterized in healthy volunteer studies of oral kratom administration. Maximum plasma concentrations are achieved approximately 1.2 to 2.0 hours after ingestion, with an elimination half-life of approximately 2.5 to 5 hours after single dosing that extends to approximately 24 hours with repeated administration [9, 10]. The compound is formed hepatically from mitragynine through CYP3A4-mediated oxidation; co-administration of the CYP3A4 inhibitor itraconazole reduces 7-hydroxymitragynine Cmax by approximately 56 percent and AUC by 43 percent while increasing mitragynine exposure 1.5-fold, confirming the CYP3A4 dependence of the metabolic conversion [10]. Preclinical studies demonstrate that chronic administration of 7-hydroxymitragynine produces opioid-type physical dependence, tolerance, and naloxone-precipitated withdrawal in mice, with cross-tolerance to morphine [11]. Respiratory depression occurs at potencies approximately 3-fold greater than morphine, though the ceiling effect characteristic of partial agonism may limit the magnitude of respiratory suppression relative to full agonists at equianalgesic doses [12].

The regulatory landscape for 7-hydroxymitragynine is rapidly evolving. In July 2025, the United States Food and Drug Administration recommended that the Drug Enforcement Administration schedule synthetic and concentrated 7-hydroxymitragynine as a Schedule I controlled substance, while indicating that natural kratom leaf products are not the focus of the scheduling recommendation [13]. Several U.S. states, including Florida, Louisiana, Mississippi, and Colorado, have independently scheduled concentrated 7-hydroxymitragynine products [13]. The compound is not approved for any therapeutic indication in any jurisdiction. This monograph reviews the chemistry, biosynthesis, and semisynthesis of 7-hydroxymitragynine; the opioid receptor pharmacology with emphasis on biased signaling; the human and animal pharmacokinetic record; the preclinical analgesic, tolerance, and dependence evidence; the limited clinical and epidemiological data; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse events and safety signals; and a comparative assessment of five kratom-derived or structurally related opioid analgesic candidates against 7-hydroxymitragynine on five competency standards.